Compositions for soothing and removing redness, methods of making, use and products

Abstract

The application provides a composition for soothing skin and removing red blood vessels, a preparation method, application and product, and relates to the technical field of cosmetics.The composition according to the application is composed of the following components in parts by weight: 50-200 parts of Vaccinium myrtillus leaf extract, 10-50 parts of palmitoyl tea extract, 2.5-5 parts of sphingomonad ferment extract, 32-64 parts of composite plant extract A and 0.12-1.2 parts of composite plant extract B; the composite plant extract A is cactus extract, radix ophiopogonis extract, oat bran extract, radix paeoniae extract and radix scrophulariae extract; the composite plant extract B is radix cnidii extract and radix notoginseng extract; the Vaccinium myrtillus leaf is subjected to microwave treatment, and then subjected to enzymatic extraction treatment with composite enzymes to obtain the Vaccinium myrtillus leaf extract. The composition has the effects of significantly removing red blood vessels and repairing sensitive skin, and can be applied to the preparation of cosmetics for soothing skin.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, specifically relating to compositions, preparation methods, applications, and products for soothing the skin and removing redness. Background Technology

[0002] Facial telangiectasia, commonly known as facial redness, is caused by decreased elasticity and increased fragility of facial capillary walls. This leads to persistent, uneven dilation and even rupture of blood vessels, resulting in vascular proliferation and causing visible redness and dilated capillaries, often accompanied by red or purplish-red patches, dots, lines, or star-shaped patterns. With age, the microcirculation slows, the number and quality of blood vessels decrease, and vasodilation accelerates. These physiological changes make the skin more prone to redness. Furthermore, physical, chemical, and hormonal stimuli can damage the skin barrier, causing the secretion of vascular endothelial growth factor (VEGF) by the skin tissue to dilate blood vessels and increase vascular permeability, resulting in facial redness. Individuals with thin and sensitive skin are more prone to redness during emotional excitement or sudden temperature changes, and are also more susceptible to redness in excessively cold or hot environments. Patients with facial redness often have a redder complexion than normal, and in severe cases, it can lead to pigmentation deposits, further damaging the skin.

[0003] Redness can also lead to the production of pro-inflammatory cytokines, a surge in matrix metalloproteinases and elastases, damage to the skin barrier function, and an overreaction to environmental stimuli; slowed microcirculation and insufficient oxygen also reduce intercellular communication, accelerating skin aging.

[0004] To soothe the skin and reduce redness, existing technologies have researched related cosmetics. Chinese invention patent CN113827520A discloses a composition for treating redness, its preparation method, and its application. This composition comprises the following components: 1-6 parts of coral algae extract, 1-5 parts of Cornus officinalis fruit extract, and 0.1-10 parts of olive leaf extract, all by weight. This composition can improve microcirculation, reduce vasodilation, decrease vascular permeability, and also has anti-inflammatory and soothing effects, strengthens the skin barrier, and is highly safe, without causing skin irritation.

[0005] Chinese invention patent CN102000006A discloses a skincare composition effective in removing facial redness. The composition comprises phase A and phase B; phase A includes water-soluble ceramide, VA palmitate, and cholesterol stearate; phase B includes a traditional Chinese medicine extract. The raw materials of the traditional Chinese medicine extract are rhubarb, sophora japonica buds, astragalus, and chamomile. Utilizing the principles of traditional Chinese medicine ("principal, assistant, adjuvant, and guide"), the various components are rationally combined and used synergistically to achieve the effect of removing facial redness.

[0006] In his article "Screening, Extraction and Mechanism of Action of Anti-allergic and Anti-irritant Active Substances for Cosmetics", Wang Haitao screened the anti-allergic and anti-irritant effects of 25 plant extracts. The results showed that cactus, dipotassium glycyrrhizate, grape seed, oat alkaloids, and mung bean fermentation products had significant anti-allergic and anti-irritant effects and could inhibit facial capillary dilation.

[0007] Existing compositions for removing facial redness mostly focus on soothing the skin, or even using moisturizing and skin-nourishing ingredients to repair damaged skin, resulting in limited effectiveness in removing redness. Furthermore, some cosmetic ingredients can even worsen skin damage, making the skin more fragile. Therefore, there is a need for a cosmetic composition with clearly defined active ingredients, where the components work synergistically to significantly remove redness, repair sensitive skin, and are non-irritating to sensitive skin. Summary of the Invention

[0008] This invention addresses the problems existing in the prior art by providing a composition, preparation method, application, and product for soothing the skin and removing redness. The components in this composition—Vaccinium myrtillaus leaf extract, palmitoyl tea extract, Sphingomonas fermentation product extract, compound plant extract A, and compound plant extract B—interact synergistically to significantly remove redness, repair sensitive skin, reduce VEGF secretion levels, lower histamine content, increase histamine release inhibition rate, and reduce hemoglobin levels. Furthermore, the Vaccinium myrtillaus leaf extract is prepared using microwave treatment and compound enzyme hydrolysis, resulting in a high content of active ingredients, which helps maintain the integrity and stability of capillaries.

[0009] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0010] First, the present invention provides a composition for soothing the skin and removing redness, which, by weight, consists of the following components: 50-200 parts of European blueberry leaf extract, 10-50 parts of palmitoyl tea extract, 2.5-5 parts of Sphingomonas fermentation product extract, 32-64 parts of compound plant extract A and 0.12-1.2 parts of compound plant extract B.

[0011] The components of the compound plant extract A are cactus extract, ophiopogon root extract, oat bran extract, peony root extract and scutellaria root extract.

[0012] The components of the compound plant extract B are Cynanchum atratum extract and Centella asiatica extract;

[0013] The preparation method of the European blueberry leaf extract is as follows: European blueberry leaves are microwave-treated and then mixed with a compound enzyme for enzymatic hydrolysis and extraction to obtain the European blueberry leaf extract.

[0014] Preferably, the composition comprises, by weight, the following components: 80-150 parts of European blueberry leaf extract, 20-40 parts of palmitoyl tea extract, 2.8-4 parts of Sphingomonas fermentation product extract, 42-54 parts of compound plant extract A and 0.5-0.8 parts of compound plant extract B.

[0015] More preferably, the composition comprises, by weight, the following components: 100 parts of European blueberry leaf extract, 30 parts of palmitoyl tea extract, 3 parts of Sphingomonas fermentation product extract, 48 parts of compound plant extract A and 0.6 parts of compound plant extract B.

[0016] Preferably, in the compound plant extract A, the weight ratio of cactus extract, ophiopogon root extract, oat bran extract, peony root extract and scutellaria root extract is 14-28:6-12:6-12:4-8:2-4.

[0017] More preferably, in the compound plant extract A, the weight ratio of cactus extract, ophiopogon root extract, oat bran extract, peony root extract and scutellaria root extract is 21:9:9:6:3.

[0018] Preferably, in the compound plant extract B, the weight ratio of Cynanchum atratum extract and Centella asiatica extract is 0.1-1:0.02-0.2.

[0019] More preferably, in the compound plant extract B, the weight ratio of Cynanchum paniculatum extract and Centella asiatica extract is 0.493-0.525:0.1.

[0020] More preferably, in the compound plant extract B, the weight ratio of Cynanchum paniculatum extract and Centella asiatica extract is 0.5:0.1.

[0021] Preferably, the preparation method of the European blueberry leaf extract is as follows: European blueberry leaves and water are mixed at a solid-liquid ratio of 1:10-20 g:mL, microwaved at a microwave power of 250-400W for 90-150s, then a compound enzyme is added, and enzymatic hydrolysis is performed at 40-50℃ for 18-36h to obtain the European blueberry leaf extract.

[0022] More preferably, the preparation method of the European blueberry leaf extract is as follows: European blueberry leaves and water are mixed at a solid-liquid ratio of 1:15 g:mL, microwaved at 320W for 120s, then a compound enzyme is added, and enzymatic hydrolysis is performed at 46℃ for 24h to obtain the European blueberry leaf extract.

[0023] More preferably, the compound enzyme is cellulase and pectinase in a weight ratio of 2:4-6.

[0024] More preferably, the compound enzyme is cellulase and pectinase in a weight ratio of 2:5.

[0025] More preferably, the amount of the compound enzyme is 0.01%-0.1% of the weight of the blueberry leaves.

[0026] More preferably, the amount of the compound enzyme is 0.07%-0.1% of the weight of the blueberry leaves.

[0027] Then, the present invention provides a method for preparing the above composition, comprising the steps of: mixing the components evenly to obtain the composition.

[0028] Furthermore, the present invention provides the application of the above composition in the preparation of cosmetics with the effects of removing redness, soothing the skin, and repairing sensitive skin.

[0029] Finally, the present invention provides a cosmetic product that has the effects of removing redness, soothing the skin, and repairing sensitive skin, comprising the above-mentioned composition.

[0030] Preferably, the cosmetic is a cosmetic that reduces VEGF secretion levels, reduces histamine content, increases histamine release inhibition rate, removes redness, and reduces hemoglobin value.

[0031] Preferably, the cosmetics are not limited to face creams, toners, lotions, face masks, makeup removers, makeup remover oils, makeup remover balms, cleansing water, facial cleansers, serums, foundations, concealers, and sunscreens.

[0032] Preferably, the cosmetic ingredients further include moisturizers, emollients, emulsifiers, solvents, pH adjusters, and thickeners.

[0033] More preferably, the ingredients of the cosmetic may also include antioxidants, chelating agents, film-forming agents, and fragrances.

[0034] More preferably, the moisturizer is a commonly used ingredient in the art, and is not limited to glycerin, polydimethylsiloxane, polydimethylsiloxane alcohol, betaine, 1,2-hexanediol, and sodium hyaluronate.

[0035] More preferably, the emollient is a commonly used ingredient in the art, and is not limited to ethylhexyl palmitate, petrolatum, caprylic / capric triglyceride, isononyl isononanoate, and phenyl polytrimethylsiloxane.

[0036] More preferably, the emulsifier is a commonly used ingredient in the art, and is not limited to cetearyl alcohol, glyceryl stearate, PEG-100 stearate, polysorbate and potassium lauryl phosphate.

[0037] More preferably, the solvent is a component commonly used in the art, and is not limited to water, methyl propylene glycol, polyacrylamide, C 13 -C 14 Isoparaffins and lauryl alcohol polyether-7.

[0038] More preferably, the pH adjuster is a component commonly used in the art, and is not limited to arginine.

[0039] More preferably, the thickener is a commonly used ingredient in the art, and is not limited to carbomer.

[0040] More preferably, the antioxidant is a component commonly used in the art, and is not limited to p-hydroxyacetophenone.

[0041] More preferably, the chelating agent is a component commonly used in the art, and is not limited to disodium EDTA.

[0042] More preferably, the film-forming agent is a component commonly used in the art, and is not limited to hydrogenated polyisobutylene.

[0043] Compared with the prior art, the present invention has the following beneficial effects:

[0044] 1. In the composition of the present invention, the extracts of European blueberry leaves, palmitoyl tea, sphingomyelin fermentation product extract, compound extract A and compound extract B interact and synergistically enhance each other, resulting in the effective removal of red blood vessels and reduction of vascular endothelial growth factor (VEGF) secretion levels; the composition has a significant effect on repairing sensitive skin, can significantly improve the protective ability of the skin barrier, and reduce transepidermal water loss.

[0045] 2. The European blueberry leaf extract in the composition of the present invention is prepared by microwave treatment and enzymatic hydrolysis with a compound enzyme. Microwave treatment can not only accelerate the leaching of active ingredients, but also has a mild extraction temperature, which does not damage the structure and activity of active ingredients. After microwave treatment, a compound enzyme is used for mild enzymatic hydrolysis to further promote the dissolution of active ingredients. The prepared European blueberry leaf extract interacts with other components to bring about excellent effects in repairing skin and removing redness. Detailed Implementation

[0046] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0047] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0048] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all chemical reagents and traditional Chinese medicine raw materials used in the embodiments of the present invention are obtained through conventional commercial channels.

[0049] In the following examples, the palmitoyl tea extract was purchased from Bayercom; the Sphingomonas fermentation product extract was purchased from Hangzhou Xiwang Biotechnology Co., Ltd.; the cactus extract, Ophiopogon japonicus root extract, oat bran extract, peony root extract, Scutellaria baicalensis root extract, Cynanchum paniculatum extract, and Centella asiatica extract were all purchased from Zhongke Houpu (Guangzhou) Technology Development Co., Ltd.; the cellulase was purchased from Nanning Dongheng Huadao Biotechnology Co., Ltd., with an enzyme activity of 10,000 U / g; and the pectinase was purchased from Nanning Dongheng Huadao Biotechnology Co., Ltd., with an enzyme activity of 10,000-30,000 U / g. Products from different manufacturers did not significantly affect the efficacy.

[0050] Examples 1-5

[0051] A composition for soothing the skin and removing redness, the specific formulation of the components by weight is shown in Table 1.

[0052] Table 1

[0053]

[0054] In the compound plant extract A of Examples 1-5, the weight ratio of cactus extract, ophiopogon root extract, oat bran extract, peony root extract and scutellaria root extract is the same, which is 21:9:9:6:3.

[0055] In the compound plant extract A of Examples 1, 4 and 5, the weight ratio of Cynanchum paniculatum extract to Centella asiatica extract was 0.5:0.1; in the compound plant extract A of Example 2, the weight ratio of Cynanchum paniculatum extract to Centella asiatica extract was 0.525:0.1; in the compound plant extract A of Example 3, the weight ratio of Cynanchum paniculatum extract to Centella asiatica extract was 0.493:0.1.

[0056] The preparation methods of the European blueberry leaf extract in Examples 1-5 are as follows: European blueberry leaves are pulverized and mixed with water at a solid-liquid ratio of 1:15 g:mL. After being treated with microwave power of 320W for 120s, a compound enzyme (cellulase and pectinase) is added and enzymatically hydrolyzed at 46℃ for 24h to obtain European blueberry leaf extract. The amount of compound enzyme added is 0.07% of the weight of European blueberry leaves, and the weight ratio of cellulase to pectinase is 2:5.

[0057] The components in Table 1 are mixed evenly to obtain the composition.

[0058] Example 6

[0059] Unlike Example 1, the preparation method of the European blueberry leaf extract is different.

[0060] The preparation method of European blueberry leaf extract is as follows: European blueberry leaves are pulverized and mixed with water at a solid-liquid ratio of 1:10 g:mL. After being treated with microwave power of 250W for 150s, a compound enzyme (cellulase and pectinase) is added and enzymatically hydrolyzed at 50℃ for 18h to obtain European blueberry leaf extract. The amount of compound enzyme added is 0.1% of the weight of European blueberry leaves, and the weight ratio of cellulase to pectinase is 2:4.

[0061] Everything else is the same as in Example 1.

[0062] Example 7

[0063] Unlike Example 1, the preparation method of the European blueberry leaf extract is different.

[0064] The preparation method of European blueberry leaf extract is as follows: European blueberry leaves are pulverized and mixed with water at a solid-liquid ratio of 1:20 g:mL. After being treated with microwave power of 400W for 90s, a compound enzyme (cellulase and pectinase) is added and enzymatically hydrolyzed at 40℃ for 36h to obtain European blueberry leaf extract. The amount of compound enzyme added is 0.1% of the weight of European blueberry leaves, and the weight ratio of cellulase to pectinase is 2:6.

[0065] Everything else is the same as in Example 1.

[0066] Comparative Example 1

[0067] Unlike Example 1, the composition contains only palmitoyl tea extract, compound plant extract A, and compound plant extract B.

[0068] The composition comprises, by weight, 30 parts palmitoyl tea extract, 48 parts compound plant extract A, and 0.6 parts compound plant extract B; wherein, compound plant extract A comprises 21 parts cactus extract, 9 parts ophiopogon japonicus root extract, 9 parts oat bran extract, 6 parts peony root extract, and 3 parts scutellaria baicalensis root extract; and compound plant extract B comprises 0.5 parts cynanchum atratum extract and centella asiatica extract. The above components are mixed evenly to obtain the composition.

[0069] Comparative Example 2

[0070] Unlike Example 1, the composition contains only two components: European blueberry leaf extract and Sphingomonas fermentation product extract.

[0071] The composition comprises, by weight, 100 parts of European blueberry leaf extract and 3 parts of Sphingosine monocytogenes fermentation product extract. The above components are mixed thoroughly to obtain the composition.

[0072] The preparation method of the European blueberry leaf extract is the same as in Example 1.

[0073] Comparative Example 3

[0074] Unlike Example 1, the extract of Sphingomonas fermentation product was replaced with salicylphytosphoside (purchased from Hefei Nahe Biotechnology Co., Ltd., CAS: 212908-67-3).

[0075] The composition, by weight, comprises: 100 parts of European blueberry leaf extract, 30 parts of palmitoyl tea extract, 3 parts of salicylyl phytosphingosine, 48 parts of compound plant extract A, and 0.6 parts of compound plant extract B; wherein, compound plant extract A comprises: 21 parts of cactus extract, 9 parts of ophiopogon japonicus root extract, 9 parts of oat bran extract, 6 parts of peony root extract, and 3 parts of scutellaria baicalensis root extract; and compound plant extract B comprises: 0.5 parts of cynanchum paniculatum extract and centella asiatica extract. The above components are mixed evenly to obtain the composition.

[0076] The preparation method of the European blueberry leaf extract is the same as in Example 1.

[0077] Comparative Example 4

[0078] Unlike Example 1, the European blueberry leaf extract was replaced with European horse chestnut (Aesculushipocastanum L.) leaf extract.

[0079] The composition, by weight, comprises: 100 parts of horse chestnut leaf extract, 30 parts of palmitoyl tea extract, 3 parts of Sphingosine monocytogenes fermentation product extract, 48 parts of compound plant extract A, and 0.6 parts of compound plant extract B; wherein, compound plant extract A comprises: 21 parts of cactus extract, 9 parts of Ophiopogon japonicus root extract, 9 parts of oat bran extract, 6 parts of peony root extract, and 3 parts of Scutellaria baicalensis root extract; and compound plant extract B comprises: 0.5 parts of Cynanchum paniculatum extract and Centella asiatica extract. The above components are mixed evenly to obtain the composition.

[0080] The preparation method of European horse chestnut leaf extract is as follows: European horse chestnut leaves are crushed and mixed with water at a solid-liquid ratio of 1:15 g:mL. After being treated with microwave power of 320W for 120s, a compound enzyme (cellulase and pectinase) is added and enzymatically hydrolyzed at 46℃ for 24h to obtain European horse chestnut leaf extract. The amount of compound enzyme added is 0.07% of the weight of European horse chestnut leaves, and the weight ratio of cellulase to pectinase is 2:5.

[0081] Comparative Example 5

[0082] Unlike Example 1, the components in Compound Plant Extract A were replaced with: 21 parts tea leaf extract, 9 parts peony root extract, 9 parts ginseng root extract, 6 parts grape seed extract and 3 parts peony root extract.

[0083] The above-mentioned extracts are prepared by water extraction, specifically: tea leaves, peony roots, ginseng roots, grape seeds and peony roots are taken as extraction raw materials, and decocted with 8 times their weight of water for 2 hours. The filtrate is concentrated and dried to obtain tea leaf extract, peony root extract, ginseng root extract, grape seed extract and peony root extract respectively.

[0084] The composition, by weight, comprises: 100 parts of European blueberry leaf extract, 30 parts of palmitoyl tea extract, 3 parts of Sphingomonas fermentation product extract, 48 parts of compound plant extract A, and 0.6 parts of compound plant extract B; wherein, compound plant extract A comprises: 21 parts of tea leaf extract, 9 parts of peony root extract, 9 parts of ginseng root extract, 6 parts of grape seed extract, and 3 parts of peony root extract; and compound plant extract B comprises: 0.5 parts of Cynanchum paniculatum extract and Centella asiatica extract. The above components are mixed evenly to obtain the composition.

[0085] The preparation method of the European blueberry leaf extract is the same as in Example 1.

[0086] Comparative Example 6

[0087] Unlike Example 1, the weight ratio of each component in the composition is different.

[0088] The composition comprises, by weight, 20 parts of European blueberry leaf extract, 100 parts of palmitoyl tea extract, 13 parts of Sphingomonas fermentation product extract, 0.6 parts of compound plant extract A, and 48 parts of compound plant extract B.

[0089] Everything else is the same as in Example 1.

[0090] Comparative Example 7

[0091] Unlike Example 1, the preparation method of European blueberry leaf extract is different, and enzymatic hydrolysis uses only one enzyme, pectinase.

[0092] The preparation method of European blueberry leaf extract is as follows: European blueberry leaves are pulverized and mixed with water at a solid-liquid ratio of 1:15 g:mL. After being treated with microwave power of 320W for 120s, 0.07% of pectinase by weight of European blueberry leaves is added, and enzymatic hydrolysis is carried out at 46℃ for 24h to obtain European blueberry leaf extract.

[0093] Everything else is the same as in Example 1.

[0094] Experiment 1: VEGF Activity Assay

[0095] VEGF (vascular endothelial growth factor) activity was detected using an ELISA kit. The detection steps are as follows:

[0096] (1) Blank control group: 1×10⁻⁶ cells per well in a 96-well plate 4 100 μL each of human umbilical vein endothelial cells (HUVECs) were seeded at a density of 10% fetal bovine serum in Ham's F-12K medium and 10% fetal bovine serum. After culturing at 37°C and 5% CO2 for 24 hours, the medium was replaced with serum-free medium. The cell culture supernatant was collected, and the secretion level of VEGF in HUVECs was detected by ELISA kit.

[0097] (2) Negative control group: 1×10⁻⁶ cells per well in a 96-well plate. 4 100 μL each of Ham's F-12K medium containing 10% fetal bovine serum and human umbilical vein endothelial cells (HUVECs) were seeded at a density of 100 μL and cultured at 37°C and 5% CO2 for 24 hours. The culture medium was then replaced with serum-free medium and inoculated with 15 mJ / cm² water. 2 After UVB irradiation, the cells were cultured for another 24 hours, and the cell culture supernatant was collected to detect the VEGF secretion level in UVB-induced HUVECs.

[0098] (3) Experimental group: In a 96-well plate, 1×10⁻⁶ mol / L of material was used per well. 4100 μL each of Ham's F-12K medium containing 10% fetal bovine serum and human umbilical vein endothelial cells (HUVECs) were seeded at a density of 15 mJ / cm². After incubation at 37°C and 5% CO₂ for 24 hours, the medium was replaced with serum-free medium, and 200 μL of each composition solution was added (preparation of composition solution: dissolve 50 mg of each composition in 5 mL of deionized water to obtain the composition solution). 2 After UVB irradiation, the cells were cultured for another 24 hours, and the cell culture supernatant was collected to detect the VEGF secretion level in HUVECs.

[0099] The results of VEGF secretion levels (%, mean ± standard deviation) in each group are shown in Table 2.

[0100] Table 2

[0101]

[0102] In Table 2, " / " indicates that there is no record of technical effect at that point.

[0103] Table 2 shows that the negative control group and the blank control group had significant differences ( ## P < 0.01 indicates 15 mJ / cm 2 UVB irradiation treatment can increase VEGF activity, induce vasodilation, and increase vascular permeability. The experimental group showed a significant difference compared to the negative control group. △ P < 0.05 △△ P < 0.01 indicates that the composition has the technical effect of reducing VEGF secretion in UVB-induced HUVECs.

[0104] The comparative example group showed a significant difference compared to the Example 1 group. & P < 0.05 &&P < 0.01 indicates that the compositions of Examples 1-7 are more effective than the comparative groups, and the compositions of the examples have a better effect in reducing vasodilation and inhibiting VEGF secretion. Specifically, the composition of Comparative Example 1 contains only palmitoyl tea extract, compound plant extract A, and compound plant extract B, while the composition of Comparative Example 2 contains only two components: European blueberry leaf extract and Sphingomonas fermentation product extract. Although the compositions of Comparative Examples 1 and 2 can also reduce VEGF activity, the technical effect is weaker. Even if the VEGF activity reduction effects of Comparative Examples 1 and 2 are added together, the effect described in the examples cannot be achieved. Therefore, the components of the compositions of the present invention interact and complement each other, resulting in a synergistic effect. Comparative Examples 4-5 replaced some components in the compositions with conventional skin-soothing components, and their effects were significantly different from the examples. The examples showed a better effect in reducing VEGF secretion levels, indicating that the components in the compositions of the present invention are not arbitrarily replaceable, and the selection of components is not conventional. The compositions of the present invention bring unexpected technical effects. After changing the weight ratio of each component in the composition in Comparative Example 6, the effect of reducing VEGF secretion level was still not as good as in the Example; in Comparative Example 7, the preparation of European blueberry leaf extract using pectinase resulted in a significantly reduced effect of the composition on reducing VEGF secretion level.

[0105] Experiment 2: Histamine Release Test from Rat Basophils (RBLs)

[0106] Histamine is a substance released by cells in response to external stimuli and allergic reactions. Histamine release increases tissue permeability, leading to tissue edema and skin itching. This study evaluated the antipruritic, soothing, and skin-repairing effects of the tested composition by detecting histamine release levels in RBL-2H3 cells.

[0107] Experimental methods: RBL-2H3 cells in the logarithmic growth phase were collected and cultured at a concentration of 2.0-3.0 × 10⁻⁶ cells / cells. 5 Cells were seeded at 100 μL / well in 24-well plates and incubated for 18-24 h. Cells were washed twice with HBSS buffer. Except for the blank control group, all other groups were treated with DNP-IgE (immunoglobulin E) to a final concentration of 1 μg / mL and incubated for 24 h to promote the full expression of the high-affinity receptor FcεRI on the surface of RBL-2H3 cells. Cells were washed twice with HBSS buffer, and 100 μL of reagent was added to each group. The reagents used for each group were as follows:

[0108] Reagents used in the sample group: Take 100 mg of each composition, add 5 mL of DMSO and dissolve thoroughly to prepare a 2% DMSO stock solution; then dilute it sequentially with serum-free MEM medium to 1.0%;

[0109] Reagent used in the blank control group: serum-free MEM culture medium;

[0110] The model control group used serum-free MEM culture medium;

[0111] Each group had 3 replicates and was incubated for 1 hour. Cells were washed twice with HBSS, and then HBSS (Hank's balanced salt solution) containing 0.5 μg / mL DNP-BSA was added to stimulate the release of histamine from RBL-2H3. The reaction was terminated by incubating for 1.5 hours and then on ice for 10 minutes. The supernatant was collected and stored at -80°C. The histamine content (ng / mL) was determined using an ELISA kit.

[0112] The formula for calculating the histamine inhibition rate is: Histamine inhibition rate (%) = (Histamine content M - Histamine content TA) / (Histamine content M - Histamine content NT) × 100%.

[0113] The histamine content and histamine inhibition rate of each group are shown in Table 3.

[0114] Table 3

[0115]

[0116] In Table 3, " / " indicates that there is no record of the relevant technical effect at that point.

[0117] In Table 3, the histamine content in the model control group was significantly different from that in the blank control group. ## P < 0.01, indicating that the histamine release model was successfully prepared. The compositions of the embodiments of this invention can all significantly inhibit the release of histamine from RBL-2H3. The inhibitory ability of the embodiment groups is better than that of the comparative groups. The histamine inhibition rate of each comparative group is significantly different from that of Example 1. △△ P < 0.01).

[0118] The comparison of histamine inhibition rate data between Comparative Examples 1 and 2 and Example 1 shows that the components in the composition of the present invention interact with each other and are indispensable, resulting in a synergistic effect. The histamine inhibition rate data between Comparative Examples 3 and 4 and Example 1 show that even if the components in the composition are replaced with other ingredients with similar effects, the significantly improved histamine inhibition rate effect described in the present invention cannot be achieved. The technical effect of Comparative Examples 3 and 4 is significantly reduced after the components are changed. After changing the weight ratio of the components in Comparative Example 6, the histamine inhibition rate is significantly lower than that of Example 1, indicating that the specific ratio between the components in the composition brings about a significantly improved technical effect.

[0119] Experiment 3: Removal of red blood vessels

[0120] Each composition was prepared into a face cream according to the following steps:

[0121] (1) 7.5g ethylhexyl palmitate, 4.5g petrolatum, 3g cetearyl alcohol, 3g caprylic / capric triglyceride, 3g isononyl isononanoate, 3g hydrogenated polyisobutylene, 2g polydimethylsiloxane, 1.5g glyceryl stearate, 0.5g PEG-100 stearate, 2g polysorbate-60, 2g phenyl polytrimethylsiloxane, 1.6g polydimethylsiloxane and 0.4g polydimethylsiloxane alcohol were mixed and stirred at 200 rpm until heated to 80°C. The mixture was stirred for 10 min until the material was homogeneous to obtain phase A.

[0122] (2) Mix 65g water, 12.5g glycerol, 2g betaine, 0.45g carbomer, 0.55g nicotinamide, 0.55g p-hydroxyacetophenone, 0.55g potassium lauryl phosphate, 0.055g sodium hyaluronate and 0.055g disodium EDTA, stir at 200rpm and heat to 80℃, stir for 10min until the material is uniform to obtain phase B;

[0123] (3) Phase A and Phase B were stirred and mixed at 400 rpm and homogenized and emulsified for 10 min; 2 g of solvent (water, methyl propylene glycol, polyacrylamide, C) was added. 13 -C 14 The weight ratio of isoparaffin and lauryl alcohol polyether-7 is 42:35:15:8. Stir at 400 rpm for 10 min until the mixture is homogeneous.

[0124] (4) Cool down to 45±3℃, add 7.5g methyl propylene glycol and 2g composition, stir at 400rpm for 20min until evenly mixed, fill and sterilize to obtain face cream containing each composition.

[0125] In the preparation process of the above face cream, the compositions used are the compositions of Example 1, Example 2, Example 3, Comparative Example 1, Comparative Example 2, and Comparative Example 4, respectively.

[0126] A total of 42 participants were recruited: healthy women aged 25-40 years; those with facial telangiectasia (spider veins) caused by chemical peels or skin allergies, clinically manifested as persistent or intermittent facial redness, with visible clusters or threads of red blood vessels on both sides of the cheekbones; participants' daily work and daily life did not require outdoor activities and they were not frequently exposed to sunlight; participants did not have serious chronic wasting diseases (such as asthma, diabetes, etc.), skin lesions, inflammation, eczema, etc.; the test area of ​​the face was free of any scars, injuries, uneven skin color, hair, or other factors that might affect the assessment; they did not have serious systemic diseases, immunodeficiency, or autoimmune diseases, and the test site had not been exposed to skin treatments, cosmetic procedures, or other tests that might affect the results; they had not used hormonal drugs or immunosuppressants within the past month; the test site had not participated in other clinical trials in the past three months; they understood the testing process, voluntarily participated in the trial, and signed an informed consent form.

[0127] Subject restrictions: During the trial, no other products with equivalent efficacy or that may affect the test results may be used on the test area; any cosmetic procedures or treatments that may affect the test results are prohibited on the test area during the trial; subjects may not change any products or skincare habits during the trial.

[0128] Testing instrument: Skin melanin and hemoglobin testing probe MX18, from the German company CK.

[0129] Subjects were randomly divided into 6 groups of 7 people each. Each group applied the corresponding composition face cream twice a day, morning and evening, 1g each time. During the study period, the cream could not be used in combination with other skincare products. After one month of continuous application, skin melanin and hemoglobin testing probes were used. The MX18 measured the red pigment values ​​on the faces of the subjects before and after applying the face cream (areas with red blood vessels, cheekbones), and recorded the average red pigment values.

[0130] Effectiveness = (Red pigment value before application - Red pigment value after application) / Red pigment value before application × 100%.

[0131] The results of hematin levels and effectiveness rates for each group of subjects are shown in Table 4.

[0132] Table 4

[0133] cream Red pigment value before application Red pigment value after application Effectiveness (%) Example 1 317.6 250.9 21.00 Example 2 316.8 253.4 20.01 Example 3 318.2 254.0 20.18 Comparative Example 1 316.0 288.3 8.77 Comparative Example 2 314.5 296.6 5.69 Comparative Example 4 319.4 276.5 13.43

[0134] As can be seen from Table 4, the composition of the present invention can significantly reduce the skin redness value, improve skin redness, and achieve the effects of soothing and repairing the skin. Compared with the examples, the composition of the comparative example has a significantly lower efficiency in reducing redness, indicating that the composition of specific components of the present invention has a significant effect in reducing skin redness.

[0135] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for soothing and reducing redness in skin, comprising, According to parts by weight, it is composed of 50-200 parts of European bilberry leaf extract, 10-50 parts of palmitoyl tea extract, 2.5-5 parts of sphingomonas ferment extract, 32-64 parts of composite plant extract A and 0.12-1.2 parts of composite plant extract B; The components of the composite plant extract A are cactus extract, radix ophiopogonis extract, oat bran extract, radix paeoniae extract and radix scrophulariae extract; The components of the composite plant extract B are radix cnidii extract and radix eriobotryae extract; The preparation method of the European bilberry leaf extract is as follows: European bilberry leaves are mixed with water at a solid-liquid ratio of 1:10-20 g:mL, microwave treatment is carried out at a microwave power of 250-400 W for 90-150 s, then composite enzymes are added, and enzymatic treatment is carried out at 40-50 ℃ for 18-36 h to obtain the European bilberry leaf extract; the composite enzymes are cellulase and pectinase at a weight ratio of 2:4-6; the amount of the composite enzymes is 0.01%-0.1% of the weight of the European bilberry leaves; the enzyme activity of the cellulase is 10,000 U / g, and the enzyme activity of the pectinase is 10,000-30,000 U / g; The palmitoyl tea extract is purchased from Bayerkome; the sphingomonas ferment extract is purchased from Hangzhou Xiwang Biological Technology Co., Ltd.; the cactus extract, radix ophiopogonis extract, oat bran extract, radix paeoniae extract, radix scrophulariae extract, radix cnidii extract and radix eriobotryae extract are all purchased from Zhongke Houpo Technology Development Co., Ltd.

2. The composition of claim 1, wherein, According to parts by weight, it is composed of 80-150 parts of European bilberry leaf extract, 20-40 parts of palmitoyl tea extract, 2.8-4 parts of sphingomonas ferment extract, 42-54 parts of composite plant extract A and 0.5-0.8 parts of composite plant extract B.

3. The composition of claim 2, wherein, According to parts by weight, it is composed of 100 parts of European bilberry leaf extract, 30 parts of palmitoyl tea extract, 3 parts of sphingomonas ferment extract, 48 parts of composite plant extract A and 0.6 parts of composite plant extract B.

4. The composition according to any one of claims 1 to 3, characterized in that, In the composite plant extract A, the weight ratio of the cactus extract, radix ophiopogonis extract, oat bran extract, radix paeoniae extract and radix scrophulariae extract is 14-28:6-12:6-12:4-8:2-4.

5. The composition according to any one of claims 1 to 3, characterized in that, In the composite plant extract B, the weight ratio of the radix cnidii extract and radix eriobotryae extract is 0.1-1:0.02-0.

2.

6. Process for the preparation of a composition according to any one of claims 1 to 5, characterized in that, The steps include: mixing the components uniformly to obtain the composition.

7. Use of the composition of any one of claims 1-5 in the preparation of a cosmetic product having the effects of removing red blood vessels, soothing the skin and repairing sensitive skin.

8. A cosmetic product having the effects of removing red blood vessels, soothing the skin and repairing sensitive skin, comprising the composition of any one of claims 1-5.

Images